Filing Details
- Accession Number:
- 0001209191-21-006880
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-02 18:00:25
- Reporting Period:
- 2021-02-01
- Accepted Time:
- 2021-02-02 18:00:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1706431 | Vir Biotechnology Inc. | VIR | Biological Products, (No Disgnostic Substances) (2836) | 812730369 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1786372 | Jay Parrish | C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-02-01 | 2,314 | $1.49 | 224,536 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-02-01 | 4,630 | $1.58 | 229,166 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-02-01 | 6,944 | $69.91 | 222,222 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-02-01 | 2,314 | $0.00 | 2,314 | $1.49 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-02-01 | 4,630 | $0.00 | 4,630 | $1.58 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
13,889 | 2027-10-05 | No | 4 | M | Direct | |
41,666 | 2028-07-19 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.
- 1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
- 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.